Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions

Melody Hermel; Andrew Chiou; Abdul Mannan Khan Minhas; Maha Inam; Carly E. Waldman; Eventine Youngblood; Sandeep Mehta; Leandro Slipczuk; Sana Sheikh; Chelsea Meloche; Adeel Khoja; Salim S. Virani

doi:10.1007/s11883-024-01193-8

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions

Melody Hermel, Andrew Chiou, Abdul Mannan Khan Minhas, Maha Inam, Carly E. Waldman, Eventine Youngblood, Sandeep Mehta, Leandro Slipczuk, Sana Sheikh, Chelsea Meloche, Adeel Khoja, Salim S. Virani

Research output: Contribution to journal › Review article › peer-review

Abstract

Purpose of Review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions. Recent Findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Summary: Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

Original language	English
Pages (from-to)	119-131
Number of pages	13
Journal	Current Atherosclerosis Reports
Volume	26
Issue number	4
DOIs	https://doi.org/10.1007/s11883-024-01193-8
Publication status	Published - Apr 2024

Keywords

Acute coronary syndrome
Cardiovascular disease
Dapagliflozin
Hyperlipidemia
Prevention
Semaglutide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11883-024-01193-8

Cite this

Hermel, M., Chiou, A., Minhas, A. M. K., Inam, M., Waldman, C. E., Youngblood, E., Mehta, S., Slipczuk, L., Sheikh, S., Meloche, C., Khoja, A., & Virani, S. S. (2024). Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions. Current Atherosclerosis Reports, 26(4), 119-131. https://doi.org/10.1007/s11883-024-01193-8

@article{aa52ed0f4f444bb6b62e8cfe572c10c2,

title = "Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions",

abstract = "Purpose of Review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions. Recent Findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Summary: Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.",

keywords = "Acute coronary syndrome, Cardiovascular disease, Dapagliflozin, Hyperlipidemia, Prevention, Semaglutide",

author = "Melody Hermel and Andrew Chiou and Minhas, {Abdul Mannan Khan} and Maha Inam and Waldman, {Carly E.} and Eventine Youngblood and Sandeep Mehta and Leandro Slipczuk and Sana Sheikh and Chelsea Meloche and Adeel Khoja and Virani, {Salim S.}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.",

year = "2024",

month = apr,

doi = "10.1007/s11883-024-01193-8",

language = "English",

volume = "26",

pages = "119--131",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Current Medicine Group",

number = "4",

}

Hermel, M, Chiou, A, Minhas, AMK, Inam, M, Waldman, CE, Youngblood, E, Mehta, S, Slipczuk, L, Sheikh, S, Meloche, C, Khoja, A & Virani, SS 2024, 'Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions', Current Atherosclerosis Reports, vol. 26, no. 4, pp. 119-131. https://doi.org/10.1007/s11883-024-01193-8

TY - JOUR

T1 - Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions

AU - Hermel, Melody

AU - Chiou, Andrew

AU - Minhas, Abdul Mannan Khan

AU - Inam, Maha

AU - Waldman, Carly E.

AU - Youngblood, Eventine

AU - Mehta, Sandeep

AU - Slipczuk, Leandro

AU - Sheikh, Sana

AU - Meloche, Chelsea

AU - Khoja, Adeel

AU - Virani, Salim S.

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.

PY - 2024/4

Y1 - 2024/4

N2 - Purpose of Review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions. Recent Findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Summary: Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

AB - Purpose of Review: Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions. Recent Findings: Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic blood pressure in middle-aged individuals (CARDIA-SSBP); long-term blood pressure control after hypertensive pregnancy with physician guided self-management (POP-HT); effect and safety of zilebesiran, an RNA interference therapy, for sustained blood pressure reduction (KARDIA-1); recaticimab add-on therapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia (REMAIN-2); efficacy and safety of lepodisiran an extended duration short-interfering RNA targeting lipoprotein(a); safety and pharmacodynamic effects of an investigational DNA base editing medicine that inactivates the PCSK9 gene and lowers LDL cholesterol (VERVE-101); automated referral to centralized pharmacy services for evidence-based statin initiation in high-risk patients; and effects of intensive blood pressure lowering in reducing risk of cardiovascular events (ESPRIT). Summary: Research presented at the 2023 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

KW - Acute coronary syndrome

KW - Cardiovascular disease

KW - Dapagliflozin

KW - Hyperlipidemia

KW - Prevention

KW - Semaglutide

UR - http://www.scopus.com/inward/record.url?scp=85186613187&partnerID=8YFLogxK

U2 - 10.1007/s11883-024-01193-8

DO - 10.1007/s11883-024-01193-8

M3 - Review article

AN - SCOPUS:85186613187

SN - 1523-3804

VL - 26

SP - 119

EP - 131

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 4

ER -

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this